Manfred Döpfner

Behavioral/Emotional Problems of Preschoolers: Caregiver/Teacher Reports From 15 Societies

This study tested societal effects on caregiver/teacher ratings of behavioral/emotional problems for 10,521 preschoolers from 15 societies. Many societies had problem scale scores within a relatively narrow range, despite differences in language, culture, and other characteristics. The small age and gender effects were quite similar across societies. The rank orders of mean item ratings were similar across diverse societies. For 7,380 children from 13 societies, ratings were also obtained from a parent. In all 13 societies, mean Total Problems scores derived from parent ratings were significantly higher than mean Total Problems scores derived from caregiver/teacher ratings, although the size of the difference varied somewhat across societies. Mean cross-informant agreement for problem scale scores varied across societies. Societies were very similar with respect to which problem items, on average, received high versus low ratings from parents and caregivers/teachers. Within every society, cross-informant agreement for item ratings varied widely across children. In most respects, results were quite similar across 15 very diverse societies.

Psychopathologisches Befund-System für Kinder und Jugendliche : (CASCAP-D)

Döpfner, M. (1999): Psychopathologisches Befund-System für Kinder und Jugendliche (CASCAP-D). Befundbogen, Glossar und Explorationsleitfaden. 28. Jan. 2013 Das Kinder-Diagnostik-System KIDS 3 beinhaltet 35 störungsübergreifende Störungen bei Kindern und Jugendlichen (EPSKI); Psychopathologisches BefundSystem für Kinder und Jugendliche (CASCAP-D); Beurteilung Psychopathologisches Befund-System für Kinder und Jugendliche (CASCAP-D). Befundbogen, Glossar und Explorationsleitfaden. von Manfred Döpfner, Walter

Trust, but verify. The errors and misinterpretations in the Cochrane analysis by O. J. Storebo and colleagues on the efficacy and safety of methylphenidate for the treatment of children and adolescents with ADHD

ObjectivenA recent Cochrane review published by O. J. Storebo and colleagues (2015) raised substantial doubts about the benefit from stimulant medication with methylphenidate in the treatment of childhood ADHD due to the overall poor quality of studies. The systematic review thus contradicts all previous reviews and meta-analyses.nnnMethodnWe here detail various examples of errors, inconsistencies, and misinterpretations in the review which led to false results and inadequate conclusions.nnnResultsnWe demonstrate that the study selection is flawed and undertaken without sufficient scientific justification resulting in an underestimation of effect sizes, which, furthermore, are inadmissibly clinically interpreted. The methodology of the assessment of bias and quality is not objective and cannot be substantiated by the data.nnnConclusionsnCochrane reviews lay claim to a high scientific quality and substantial relevance for evidence-based clinical decisions. The systematic review by Storebo and colleagues (2015) illustrates that, despite adhering to strict standards and high-quality protocols, even Cochrane works should be critically read and verified, sometimes with surprising results.

[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guideline. Part 1: overview and recommendations].

Langwirksame Medikamente zur Behandlung der hyperkinetischen St?rungen. Teil 1: ?bersicht und EmpfehlungenA panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available.Zusammenfassung: Ein Expertengremium aus mehreren europaischen Landern hat samtliche verfugbaren veroffentlichten und unveroffentlichten Studienergebnisse zum Einsatz von langwirksamen Medikamenten bei ADHS und hyperkinetischer Storung analysiert und auf dieser Grundlage Empfehlungen zur praktischen Anwendung dieser Arzneimittel entwickelt: Auf der Grundlage der Analyse wurde gefolgert: (1) Langwirksame Praparate sollten zugelassen sein und eingesetzt werden; (2) Sie sollen kurzwirksame Arzneimittel (aus Kostengrunden und wegen der hoheren Flexibilitat der Dosierung) nicht vollstandig ersetzen. Individuelle Therapieoptionen sind erforderlich. (3) Sowohl ATX als auch Stimulanzien mit retardierter Freisetzung sollten zur Verfugung stehen. Zusatzlich werden ausfuhrliche Empfehlungen gegeben, nach welchen Kriterien ein spezifisches Praparat fur den individuellen Patienten ausgewahlt werden sollte.A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder. Based on this analysis detailed recommendations about the use of these drugs in practice have been developed: (1) Long-acting preparations should be licensed and used; (2) They should not completely replace short-acting drugs (which will be the initial treatment for many children in view of cost and the greater flexibility of dosing). Individual clinical choices are necessary. (3) Both ATX and extended-release stimulants should be available. In addition, detailed recommendations will be made with regard to the criteria to be applied in choosing a preparation for the individual patient.

[Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications]

A panel of experts from several European countries has accomplished a systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorders, on the basis of which practical recommendations for the application of these medications have been developed. The current article outlines results of this analysis, comparing the effect sizes and numbers-needed to-treat for extended-release stimulant preparations and atomoxetine (ATX). It is concluded (1) that long-acting preparations should be licensed and used. (2) However, they should not completely replace short-acting medications, in view of costs as well as the greater flexibility of dosing. Individual choices of therapy are necessary. (3) Both ATX and retarded-release stimulants should be available.Langwirksame Medikamente zur Behandlung der hyperkinetischen Storungen. Teil 2: Ein quantitativer Vergleich der langwirksamen Praparate

Aggressivität und Dissozialität von Kindern und Jugendlichen in Deutschland

Die internationale Forschung hat in den letzten Jahrzehnten wichtige Erkenntnisse uber die Ursachen und den Entwicklungsverlauf von aggressivem und dissozialem Verhalten geliefert und auch die Wirksamkeit von Interventionen in vielen Studien uberpruft (vgl. Dopfner & Lehmkuhl, 1995). Im deutschen Sprachraum wurde dieses Thema jedoch erschreckend wenig bearbeitet.

Cannabis als ADHS-Medikation: Mehr Risiken als Nutzen

(...) erforderlich machen, zu bleibender oder schwerwiegender Behinderung (...) führen.“ Zur Zusammenarbeit von MDK und Krankenkassen wird der zeitliche Ablauf erläutert. Demnach werden dem MDK die Fristen von der Krankenkasse mitgeteilt und die Frist wird unterbrochen, wenn die Unterlagen nicht vollständig sind. Außerdem wird dargelegt, wie die Meldung der Krankenkasse über die bisherige x82erapie auszusehen hat: Sie muss demnach in einer Excel-Tabelle alle verordneten beziehungsweise abgegebenen Medikamente für diesen Patienten enthalten.

Psychotherapeutische Konzepte in der Kinder- und Jugendpsychiatrie

Der Entwicklung psychotherapeutischer Konzepte und ihrer Evaluation kommt in der Kinder- und Jugendpsychiatrie eine zentrale Bedeutung zu. Hierbei ergeben sich vor allem folgende Fragestellungen: Wie wirkt eine Behandlungsmethode, wie ist ihre Effizienz im Vergleich zu anderen Methoden einzuschatzen, fur welches Indikationsspektrum ist sie geeignet und wann sollte sie moglichst nicht angewandt werden? Ihre Durchfuhrung mus bestimmten Qualitatsstandards entsprechen, wobei in der Facharztweiterbildung die hierzu notwendigen praxeologischen Fahigkeiten vermittelt werden sollten.